← FDA DRUG APPROVALS

FDA NDA · NDA020903

REBETOL

Sponsor: MERCK SHARP DOHME

APPLICATION
NDA020903
TYPE
NDA
ORIGINAL APPROVAL
1998-06-03
LATEST ACTION
2022-03-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

REBETOLDiscontinued
RIBAVIRIN 200MG **Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy** · CAPSULE · ORAL
REBETOL · ReferenceDiscontinued
RIBAVIRIN 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE · ORAL

Approval history

2022-03-16Labeling · Supplement 57 · standardLetterAP
2020-01-28Labeling · Supplement 56 · standardLetterAP
2019-05-02Labeling · Supplement 55 · standardLabelAP
2015-05-21Labeling · Supplement 53 · standardLabelAP
2013-11-15Labeling · Supplement 52 · standardLabelAP
2013-05-31Labeling · Supplement 51 · standardLetterAP
2013-02-06Labeling · Supplement 50 · 901 requiredLetterAP
2013-01-04Manufacturing (CMC) · Supplement 49 · priorityAP
2011-05-06REMS · Supplement 48LetterAP
2010-10-28Labeling · Supplement 46 · unknownLabelAP
2009-11-06Labeling · Supplement 45 · standardLetterAP
2009-11-06Labeling · Supplement 43 · standardLetterAP
2009-11-06Labeling · Supplement 44 · standardLetterAP
2009-11-06Labeling · Supplement 42 · standardLabelAP
2007-12-04Labeling · Supplement 40 · standardLabelAP
2007-04-13Labeling · Supplement 39 · standardLetterAP
2006-08-25Labeling · Supplement 38 · standardLabelAP
2004-06-24Labeling · Supplement 34 · standardLabelAP
2004-06-08Labeling · Supplement 33 · standardLabelAP
2003-10-10Labeling · Supplement 32 · standardLabelAP
2003-07-09Labeling · Supplement 30 · standardLetterAP
2003-06-09Labeling · Supplement 28 · standardLetterAP
2003-05-21Labeling · Supplement 29 · standardLabelAP
2002-12-20Manufacturing (CMC) · Supplement 27 · priorityAP
2002-11-13Labeling · Supplement 25 · standardLetterAP
2002-11-13Labeling · Supplement 24 · standardAP
2002-09-03Labeling · Supplement 23 · standardLabelAP
2002-03-06Efficacy · Supplement 20 · unknownReviewAP
2002-02-21Labeling · Supplement 15 · standardLetterAP
2002-01-03Manufacturing (CMC) · Supplement 21 · priorityAP
2001-12-28Efficacy · Supplement 13 · standardLetterAP
2001-11-05Manufacturing (CMC) · Supplement 17 · priorityAP
2001-10-31Labeling · Supplement 10 · standardLabelAP
2001-10-24Labeling · Supplement 14 · standardLabelAP
2001-08-29Manufacturing (CMC) · Supplement 19 · priorityAP
2001-07-25Labeling · Supplement 11 · standardLabelAP
2001-07-25Labeling · Supplement 8 · standardReviewAP
2001-07-25Labeling · Supplement 16 · standardLetterAP
2001-07-25Labeling · Supplement 12 · standardReviewAP
2001-03-13Labeling · Supplement 7 · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →